Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia

Ursula Winters, Sai Daayana, John T. Lear, Anne E. Tomlinson, Eyad Elkord, Peter L. Stern, Henry C. Kitchener

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Purpose: High-risk human papillomavirus (HPV)-associated vulval intraepithelial neoplasia (VIN) is difficult to treat by excision or ablation because of high recurrence rates. Small studies of photodynamic therapy (PDT) and imiquimod treatments have shown some success and function at least in part through stimulation of local immune responses. Indeed, there is evidence that immunosuppressed individuals have higher rates of VIN, suggesting immune control is relevant. Experimental Design: In the study, 20 women with high-grade VIN were treated with topical imiquimod and the PDT sequentially.Vulval biopsy and blood were taken pretreatment and, after imiquimod and PDT, with follow up for 1 year. Clinical response was assessed by measuring lesion size. Biopsies were analyzed for HPV DNA and tumor-infiltrating lymphocytes including T regulatory cells. Results: The treatment was well-tolerated. There was an overall response rate of 55% by intention treat and 64% per protocol. The 52-week symptom response was 65% asymptomatic, compared with 5% at baseline. The nonresponders showed a significantly higher level of T regulatory cells in the lesions after imiquimod treatment. Conclusions: The response rates are clinically relevant, and the treatment regimen was feasible for the majority. Initial nonresponders to imiquimod seem to be relatively refractory, and this may derive from their unfavorable local immune environment, in particular, the increased proportions of T regulatory cells, possibly the limiting action and/or development of any HPV T-cell immunity. The potential benefit of this treatment is its ability to treat multifocal disease.

Original languageEnglish
Pages (from-to)5292-5299
Number of pages8
JournalClinical Cancer Research
Volume14
Issue number16
DOIs
Publication statusPublished - 15 Aug 2008
Externally publishedYes

Fingerprint

imiquimod
Photochemotherapy
Regulatory T-Lymphocytes
Neoplasms
Tumor-Infiltrating Lymphocytes
Biopsy
Therapeutics
Aptitude
Human Development
Immunity
Research Design
T-Lymphocytes
Recurrence
DNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. / Winters, Ursula; Daayana, Sai; Lear, John T.; Tomlinson, Anne E.; Elkord, Eyad; Stern, Peter L.; Kitchener, Henry C.

In: Clinical Cancer Research, Vol. 14, No. 16, 15.08.2008, p. 5292-5299.

Research output: Contribution to journalArticle

Winters, Ursula ; Daayana, Sai ; Lear, John T. ; Tomlinson, Anne E. ; Elkord, Eyad ; Stern, Peter L. ; Kitchener, Henry C. / Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 16. pp. 5292-5299.
@article{81bcc019d52b45b8945eeb06712445cc,
title = "Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia",
abstract = "Purpose: High-risk human papillomavirus (HPV)-associated vulval intraepithelial neoplasia (VIN) is difficult to treat by excision or ablation because of high recurrence rates. Small studies of photodynamic therapy (PDT) and imiquimod treatments have shown some success and function at least in part through stimulation of local immune responses. Indeed, there is evidence that immunosuppressed individuals have higher rates of VIN, suggesting immune control is relevant. Experimental Design: In the study, 20 women with high-grade VIN were treated with topical imiquimod and the PDT sequentially.Vulval biopsy and blood were taken pretreatment and, after imiquimod and PDT, with follow up for 1 year. Clinical response was assessed by measuring lesion size. Biopsies were analyzed for HPV DNA and tumor-infiltrating lymphocytes including T regulatory cells. Results: The treatment was well-tolerated. There was an overall response rate of 55{\%} by intention treat and 64{\%} per protocol. The 52-week symptom response was 65{\%} asymptomatic, compared with 5{\%} at baseline. The nonresponders showed a significantly higher level of T regulatory cells in the lesions after imiquimod treatment. Conclusions: The response rates are clinically relevant, and the treatment regimen was feasible for the majority. Initial nonresponders to imiquimod seem to be relatively refractory, and this may derive from their unfavorable local immune environment, in particular, the increased proportions of T regulatory cells, possibly the limiting action and/or development of any HPV T-cell immunity. The potential benefit of this treatment is its ability to treat multifocal disease.",
author = "Ursula Winters and Sai Daayana and Lear, {John T.} and Tomlinson, {Anne E.} and Eyad Elkord and Stern, {Peter L.} and Kitchener, {Henry C.}",
year = "2008",
month = "8",
day = "15",
doi = "10.1158/1078-0432.CCR-07-4760",
language = "English",
volume = "14",
pages = "5292--5299",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia

AU - Winters, Ursula

AU - Daayana, Sai

AU - Lear, John T.

AU - Tomlinson, Anne E.

AU - Elkord, Eyad

AU - Stern, Peter L.

AU - Kitchener, Henry C.

PY - 2008/8/15

Y1 - 2008/8/15

N2 - Purpose: High-risk human papillomavirus (HPV)-associated vulval intraepithelial neoplasia (VIN) is difficult to treat by excision or ablation because of high recurrence rates. Small studies of photodynamic therapy (PDT) and imiquimod treatments have shown some success and function at least in part through stimulation of local immune responses. Indeed, there is evidence that immunosuppressed individuals have higher rates of VIN, suggesting immune control is relevant. Experimental Design: In the study, 20 women with high-grade VIN were treated with topical imiquimod and the PDT sequentially.Vulval biopsy and blood were taken pretreatment and, after imiquimod and PDT, with follow up for 1 year. Clinical response was assessed by measuring lesion size. Biopsies were analyzed for HPV DNA and tumor-infiltrating lymphocytes including T regulatory cells. Results: The treatment was well-tolerated. There was an overall response rate of 55% by intention treat and 64% per protocol. The 52-week symptom response was 65% asymptomatic, compared with 5% at baseline. The nonresponders showed a significantly higher level of T regulatory cells in the lesions after imiquimod treatment. Conclusions: The response rates are clinically relevant, and the treatment regimen was feasible for the majority. Initial nonresponders to imiquimod seem to be relatively refractory, and this may derive from their unfavorable local immune environment, in particular, the increased proportions of T regulatory cells, possibly the limiting action and/or development of any HPV T-cell immunity. The potential benefit of this treatment is its ability to treat multifocal disease.

AB - Purpose: High-risk human papillomavirus (HPV)-associated vulval intraepithelial neoplasia (VIN) is difficult to treat by excision or ablation because of high recurrence rates. Small studies of photodynamic therapy (PDT) and imiquimod treatments have shown some success and function at least in part through stimulation of local immune responses. Indeed, there is evidence that immunosuppressed individuals have higher rates of VIN, suggesting immune control is relevant. Experimental Design: In the study, 20 women with high-grade VIN were treated with topical imiquimod and the PDT sequentially.Vulval biopsy and blood were taken pretreatment and, after imiquimod and PDT, with follow up for 1 year. Clinical response was assessed by measuring lesion size. Biopsies were analyzed for HPV DNA and tumor-infiltrating lymphocytes including T regulatory cells. Results: The treatment was well-tolerated. There was an overall response rate of 55% by intention treat and 64% per protocol. The 52-week symptom response was 65% asymptomatic, compared with 5% at baseline. The nonresponders showed a significantly higher level of T regulatory cells in the lesions after imiquimod treatment. Conclusions: The response rates are clinically relevant, and the treatment regimen was feasible for the majority. Initial nonresponders to imiquimod seem to be relatively refractory, and this may derive from their unfavorable local immune environment, in particular, the increased proportions of T regulatory cells, possibly the limiting action and/or development of any HPV T-cell immunity. The potential benefit of this treatment is its ability to treat multifocal disease.

UR - http://www.scopus.com/inward/record.url?scp=52649178275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649178275&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-4760

DO - 10.1158/1078-0432.CCR-07-4760

M3 - Article

C2 - 18698049

AN - SCOPUS:52649178275

VL - 14

SP - 5292

EP - 5299

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -